Biotricity receives Health Canada clearance for Biotres

Biotricity announced its Health Canada approval for expansion into the $1.56 billion Canadian Cardiology Devices market. Cardiovascular disease imposes a staggering $21.2 billion annual cost in Canada alone, accounting for 11.6% of the entire Canadian health care cost, the approval of Biotres by Health Canada comes at an opportune time.